In the wake of the debate sparked by off-label use of Roche’s cancer blockbuster Avastin being linked to eye infections, a group of European patient organisations have raised concerns about the unlicensed use of medicines. The European Alliance for Access to Safe Medicines (EAASM), the European Federation of Neurological Associations, the European Men’s Health Forum and the European Depression Association have issued a statement calling for a professional code of practice about off-label use.
